Milestone (NASDAQ: MIST) director receives 77,000 stock options grant

Rhea-AI Filing Summary

Milestone Pharmaceuticals Inc. director Lisa M. Giles received a grant of stock options covering 77,000 shares of common stock. The options have an exercise price of $1.2200 per share and expire on June 10, 2036. They vest in twelve equal monthly installments starting July 10, 2026, or will be fully vested by the next annual stockholder meeting if she continues providing service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Giles Lisa M.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	77,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 77,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 77,000 options Exercise price: $1.2200 per share Underlying shares: 77,000 shares +2 more

5 metrics

Options granted 77,000 options Stock Option (right to buy) grant to director Lisa M. Giles

Exercise price $1.2200 per share Strike price for 77,000 stock options

Underlying shares 77,000 shares Common Stock underlying the option grant

Expiration date June 10, 2036 Option term end for granted stock options

Vesting schedule 12 equal monthly installments Beginning July 10, 2026, or fully vested by next annual meeting

Key Terms

Stock Option (right to buy), exercise price, vesting, annual meeting of the stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 1.2200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"This option will vest in twelve (12) equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of the stockholders financial

"fully vested on the date of next annual meeting of the stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Giles Lisa M.

(Last) (First) (Middle)

C/O MILESTONE PHARMACEUTICALS INC.

1111 DR. FREDERIK-PHILIPS BLVD, STE 420

(Street)

MONTREAL H4M 2X6

(City) (State) (Zip)

QUEBEC, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Milestone Pharmaceuticals Inc. [ MIST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.22	06/10/2026		A		77,000		(1)	06/10/2036	Common Stock	77,000	$0	77,000	D

Explanation of Responses:

1. This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.

	/s/ Joseph Oliveto, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Milestone Pharmaceuticals (MIST) report for Lisa M. Giles?

Milestone Pharmaceuticals reported that director Lisa M. Giles received a grant of stock options for 77,000 shares of common stock. These options represent a compensation award, not an open-market purchase or sale of Milestone Pharmaceuticals (MIST) shares.

How many Milestone Pharmaceuticals (MIST) options were granted and at what price?

Lisa M. Giles was granted stock options covering 77,000 underlying shares of Milestone Pharmaceuticals common stock. The options have an exercise price of $1.2200 per share, meaning she can buy shares at that price once the options vest.

What is the vesting schedule for Lisa M. Giles’ Milestone (MIST) stock options?

The 77,000 stock options granted to Lisa M. Giles vest in twelve equal monthly installments starting on July 10, 2026. They will in any case be fully vested by the next annual meeting of Milestone Pharmaceuticals’ stockholders, subject to her continued service.

When do Lisa M. Giles’ Milestone Pharmaceuticals (MIST) stock options expire?

The stock options granted to Lisa M. Giles expire on June 10, 2036. After that expiration date, she can no longer exercise the options to buy Milestone Pharmaceuticals common stock at the $1.2200 exercise price.

Is Lisa M. Giles’ Milestone (MIST) Form 4 transaction a market buy or sell?

The Form 4 reports a grant of stock options as compensation, coded as an acquisition (A), not an open-market buy or sell. No common shares were purchased or sold in the market; the transaction involves derivative securities only.